LysaKare is a clear and colourless solution for infusion, supplied in a single-use flexible plastic bag. It contains the active substances arginine and lysine, two different amino acids.


LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.

Summary of Product Characteristics (SmPC) 

DenmarkEstonia  Finland  Iceland  Latvia  Lithuania  Norway  Sweden

Practical information about LysaKare

The marketing authorisation holder for LysaKare is Advanced Accelerator Applications, distributed in the Nordic and Baltic regions by SAM Nordic.

Further information about this medicinal product can be obtained from the representative of the marketing authorisation holder: SAM Nordic, Tel: +46 8 720 58 22,